Janssen Biotech is partnering with Miraca Life Sciences and its InformTx therapeutic drug monitoring service to develop the Janssen 2Inform program for patients with inflammatory bowel disease (IBD) being treated with Remicade (infliximab).
The InformTx monitoring service allows clinicians to personalize IBD management for patients by assessing drug and anti-drug antibody blood levels for the biologic drugs Remicade, Humira (adalimumab), Cimzia (certolizumab), and Entyvio (vedolizumab), mainly addressing Crohn’s disease and ulcerative colitis.
The Janssen 2Inform program will provide two free therapeutic drug monitoring tests per year for patients with IBD who are receiving treatment with FDA-approved Remicade.
“The treatment goal with IBD is to get symptoms under control and in remission as quickly as possible, but treating these diseases is not a one-size-fits-all approach as each patient responds differently to medication,” Dr. Andrew Greenspan, M.D., vice president of medical affairs at Janssen Biotech, said in a press release. “Through Janssen 2Inform, TDM test results can help HCPs evaluate how a patient is responding to Remicade and, in turn, identify steps to optimize the patient’s response.”
The program works by collecting blood tests from a patient and sending them overnight to be analyzed by Miraca Life Sciences. The results are later reported electronically to the physician within three to five business days.
Evidence showing that serum anti-tumor necrosis factor drug and anti-drug antibody concentrations are associated with clinical outcomes in IBD has accumulated in recent years. This confirms the importance of using widespread therapeutic drug monitoring (TDM) for maximizing drug effectiveness, minimizing toxicity, and maintaining remission.
Studies like those reported in this IBD News Today article from 2014 contribute to the recognition that monitoring tests during therapeutics also has a significant impact on health budgets, with a saving of 25 percent over five years of treatment.
“We are committed to providing doctors with the tools they need to personalize a treatment plan for their patients living with IBD,” said Dr. Jay Popp, MD, Janssen’s medical director. “In our research, we found many doctors don’t use TDM because it isn’t covered by insurance, so Janssen is proud to launch Janssen 2Inform as a solution to this access barrier, and to help improve IBD patient care.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?